

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

25 Feb 2026

### Immunogenicity and safety evaluation of Pastocovac Plus as the booster dose in Iranian adults aged from 18 to 80 who received two doses of Sinopharm and Astrazeneca

#### Protocol summary

##### Study aim

Immunogenicity and safety evaluation of PastoCovac Plus as the booster dose in Iranian adults aged from 18 to 80 who received two doses of Sinopharm and Astrazeneca

##### Design

In this study, 190 adults (18 to 80 years old) were immunized with 2 doses of Sinopharm, Astrazeneca vaccine, which are administered in parallel and non-randomly.

##### Settings and conduct

Pasteur Institute of Iran

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: People 18 to 80 years of age who have received two doses of Sinopharm or Astrazeneca vaccine and three to six months after the second dose. Inclusion criteria: Individuals with uncontrolled underlying disease and a history of receiving any type of vaccination other than Covid-19 three months prior to enrollment.

##### Intervention groups

First dose: Sinopharm, Second dose: Sinopharm, Booster: Pastocovac Plus (Iran). First dose: Astrazeneca Second dose: Astrazeneca Booster: Pastocovac Plus (Iran). First dose: Sinopharm, Second dose: Sinopharm, Booster: Sinopharm. Groups of 20 people include: First dose: Astrazeneca, second dose: Astrazeneca, third dose: Astrazeneca, First dose: Astrazeneca, second dose: Astrazeneca, third dose: Pastocovac Plus (Cuba)

##### Main outcome variables

SARS-CoV-2 Anti SPIKE IgG;

#### General information

##### Reason for update

It is an observational study that was clarified in the methods.

##### Acronym

#### IRCT registration information

IRCT registration number: **IRCT20131221015878N3**

Registration date: **2022-01-18, 1400/10/28**

Registration timing: **registered\_while\_recruiting**

Last update: **2022-02-20, 1400/12/01**

Update count: **2**

#### Registration date

2022-01-18, 1400/10/28

#### Registrant information

##### Name

Amitis Ramezani

##### Name of organization / entity

Pasteur Institute of Iran

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 6696 8852

##### Email address

amitiramezani@hotmail.com

#### Recruitment status

**Recruitment complete**

#### Funding source

#### Expected recruitment start date

2021-12-12, 1400/09/21

#### Expected recruitment end date

2022-04-10, 1401/01/21

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

Immunogenicity and safety evaluation of Pastocovac Plus

as the booster dose in Iranian adults aged from 18 to 80 who received two doses of Sinopharm and Astrazeneca

#### Public title

Immunogenicity and safety evaluation of Pastocovac Plus in Iranian adults who received two doses of Sinopharm and Astrazeneca

#### Purpose

Prevention

#### Inclusion/Exclusion criteria

##### Inclusion criteria:

Signed informed written consent Able to follow the vaccination schedules, visits and tests General health and controlled underlying diseases (based on the physician's recommendation) Iranian citizenship Resident in Tehran Both sexes (male and female) Aged above 18 years Receiving 2 doses of Sinopharm vaccine with 28±5 days interval Receiving 2 doses of Astrazeneca vaccine with 3 to 4 months interval All candidates whose second vaccination either Sinopharm or Astrazeneca was done 3 to 6 prior to enrollment.

##### Exclusion criteria:

Having a history of vaccination against Covid-19 with other available vaccines History of COVID-19 based on laboratory or clinical evidence after receiving the vaccine History of any vaccinations except COVID-19 within 3 months prior to enrollment Pregnant or breastfeeding women or those who intend to become pregnant up to 3 months after the booster dose injection. Having uncontrolled hypertension (cytological pressure greater than 140 or diastolic pressure greater than 90 mm Hg) History of receiving blood or blood products such as immunoglobulin in the last three months Suffering from chronic kidney disease (GFR less than 30) Suffering from chronic liver disease (liver enzymes more than 5 times normal: 150ALT≥, 100AST≥) Suffering from uncontrolled asthma (Having had an asthma attack in the last three months) History of severe allergic reaction (anaphylaxis) to the vaccine during a person's lifetime History of treatment with immunosuppressive drugs 1 month before the booster injection (including oral and inhaled steroids (does not include topical steroids), cytostatic, interferon, immunoferon, transfer factor, Biomodulin T, any type of gammaglobin, levamisole , Heberferon, thymosin or any other immunomodulatory drug (including patients taking the above drugs due to an underlying disease). Having a fever or acute illness during the 7 days before the injection or on the day of the booster injection Suffering from an unstable heart disease

#### Age

From 18 years old to 80 years old

#### Gender

Both

#### Phase

N/A

#### Groups that have been masked

No information

#### Sample size

Target sample size: 190

More than 1 sample in each individual

Number of samples in each individual: 2

Blood sample before he booster dose and one month after that

#### Randomization (investigator's opinion)

N/A

#### Randomization description

#### Blinding (investigator's opinion)

Not blinded

#### Blinding description

#### Placebo

Not used

#### Assignment

Parallel

#### Other design features

It is an observational study; which we follow the immunological response of those who receive an accepted booster vaccine (PastoCovac Plus).

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Pasteur Institute of Iran (Research Ethics Committee)

##### Street address

No. 69, Pasteur Ave., Tehran , Iran

##### City

Tehran

##### Province

Tehran

##### Postal code

1316943551

#### Approval date

2021-12-12, 1400/09/21

#### Ethics committee reference number

IR.PII.REC.1400.076

## Health conditions studied

### 1

#### Description of health condition studied

Covid-19

#### ICD-10 code

U11

#### ICD-10 code description

Need for immunization against COVID-19

### 2

#### Description of health condition studied

Covid-19

#### ICD-10 code

U07

#### ICD-10 code description

COVID-19, virus identified & not identified

## Primary outcomes

### 1

#### Description

Increased Anti-Spike headline

#### Timepoint

At the beginning of the study (before the intervention) and one month after the intervention (receiving a booster dose)

#### Method of measurement

Antibody titer with ELISA Kit Anti-SARS-CoV-2 QuantiVac ELISA (IgG) Kit, Euroimmun co.

### 2

#### Description

Quadrupling the neutralizing antibody titer

#### Timepoint

At the beginning of the study (before the intervention) and one month after the intervention (receiving a booster dose)

#### Method of measurement

SARS-CoV-2 Neutralizing Ab Elisa kit

## Secondary outcomes

### 1

#### Description

Evaluating safety of Booster dose

#### Timepoint

During 30 mins till one month after intervention

#### Method of measurement

Visiting cases(days 0,30) and follow up cases every two weeks by phone call.

## Intervention groups

### 1

#### Description

Intervention group: Intervention group: People receiving two doses of Sinopharm as Pastocovac Plus booster.

#### Category

Prevention

### 2

#### Description

Intervention group: Intervention group: People receiving two doses of AstraZeneca as a Pastocovac Plus booster.

#### Category

Prevention

### 3

#### Description

Intervention group: People receiving two doses of Sinopharm as a Sinopharm booster.

#### Category

Prevention

### 4

#### Description

Control group: People receiving two doses of AstraZeneca as AstraZeneca booster.

#### Category

Prevention

### 5

#### Description

Control group: People receiving two doses of AstraZeneca as a Pastocovac Plus (Cuba) booster.

#### Category

Prevention

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Vaccination Department of Pasteur Institute of Iran

##### Full name of responsible person

Dr. Sarah Dahmardeh

##### Street address

No. 69, Pasteur Ave., Tehran , Iran

##### City

Tehran

##### Province

Tehran

##### Postal code

1316943551

##### Phone

+98 21 6695 3311

##### Fax

+98 21 6646 5132

##### Email

sarahdahmardeh@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Pasture Institute of Iran

##### Full name of responsible person

Dr.Alireza Biglari

##### Street address

No. 69, Pasteur Ave., Tehran , Iran

##### City

Tehran

##### Province

Tehran

##### Postal code

1316943551

##### Phone

+98 21 6695 3311

##### Email

biglari63@hotmail.com

##### Grant name

**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**  
Pasture Institute of Iran

**Proportion provided by this source**  
100

**Public or private sector**  
Public

**Domestic or foreign origin**  
Domestic

**Category of foreign source of funding**  
*empty*

**Country of origin**

**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**  
Pasture Institute of Iran

**Full name of responsible person**  
Sarah Dahmardeh

**Position**  
General Practitioner

**Latest degree**  
Medical doctor

**Other areas of specialty/work**  
General Practitioner

**Street address**  
No. 69, Pasteur Ave., Tehran , Iran

**City**  
Tehran

**Province**  
Tehran

**Postal code**  
1316943551

**Phone**  
+98 21 6695 3311

**Email**  
sarahdahmardeh@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Pasture Institute of Iran

**Full name of responsible person**  
Amitis Ramezani

**Position**  
Professor

**Latest degree**  
Specialist

**Other areas of specialty/work**  
Infectious diseases

**Street address**  
No.69, Ave pasteur, Tehran, Iran

**City**  
Tehran

### Province

Tehran

**Postal code**  
131693551

**Phone**  
+98 21 6411 2812

**Email**  
Amitisramezani@hotmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Pasture Institute of Iran

**Full name of responsible person**  
Anahita Bavand

**Position**  
Laboratory Medicine

**Latest degree**  
Master

**Other areas of specialty/work**  
Laboratory Medicine

**Street address**  
No. 69, Pasteur Ave., Tehran , Iran

**City**  
Tehran

**Province**  
Tehran

**Postal code**  
1316943551

**Phone**  
+98 21 6695 3311

**Email**  
Anahita.bavand@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Yes - There is a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

### Title and more details about the data/document

We are preparing our data-sharing plan.

### When the data will become available and for how long

We are preparing our data-sharing plan.

### To whom data/document is available

We are preparing our data-sharing plan.

### Under which criteria data/document could be used

We are preparing our data-sharing plan.

**From where data/document is obtainable**

We are preparing our data-sharing plan.

**What processes are involved for a request to access**

**data/document**

We are preparing our data-sharing plan.

**Comments**